Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a clinical-stage biotechnology company that has demonstrated a successful shift in focus to royalty-bearing assets and strategic partnerships, while also continuing to develop and test their promising drugs for autoimmune and inflammatory diseases. Their recent legal disputes with GSK/Tesaro may impact their future, but the potential revenue and growth from their assets and collaborations make AnaptysBio an attractive investment opportunity. With successful clinical trials and promising results, AnaptysBio has a positive outlook for future profitability and shareholder value.

Bears say

AnaptysBio is facing several challenges, including an ongoing lawsuit with GSK and potential risks that Jemperli royalties could go away. Despite the potential for revenue from Jemperli and other antibody candidates in clinical development, the overall financial health of the company may be hindered by its low operational expenses and dependence on royalty revenue streams. Additionally, with the completion of the spin-off of First Tracks Biotherapeutics, AnaptysBio may face difficulties in managing its clinical development programs and mitigating operating expenses. This, combined with the uncertain outcomes of its various clinical trials, leads to a negative outlook on the stock.

AnaptysBio (ANAB) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 11 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.